UCLA Health researchers say study findings uncover Huntington's disease mechanisms and pave new ways to develop treatments.

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in mice with Huntington’s disease by more than 80%. The therapy had no ...

Finding biomarkers that track with Huntington’s disease progression, particularly at very early ... and a growing body of ...

Polyglutamine (polyQ) diseases, a group of dominantly inherited CNS disorders, are caused by an abnormal expansion of ...

and the drug's predicted suppression of the PMS1 protein, SKY-0515, if approved, could make a meaningful difference in Huntington's patients' lives." Huntington's disease is a rare hereditary ...

PARK2/PARKIN PARK2 is characterized by genetic defects in the parkin protein, an E3 ubiquitin ... α-synuclein Complex I and IV deficiency Huntington's disease Neuronal intra-nuclear and intra ...